What is the recommended prophylactic cranial irradiation (PCI) dose for patients with leukemia?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 21, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Prophylactic Cranial Irradiation Dose in Leukemia

For patients with acute lymphoblastic leukemia (ALL) requiring prophylactic cranial irradiation, the recommended dose is 18 Gy delivered at 1.5-1.8 Gy per fraction. 1

Current Guideline Recommendations

The most recent NCCN guidelines (2025) explicitly state that when cranial radiation is indicated for pediatric ALL patients, 18 Gy at 1.5-1.8 Gy/fraction is the standard dosing regimen 1. This represents the consensus approach across major treatment protocols.

Critical Context: When PCI Should NOT Be Used

The 2026 American Society of Hematology guidelines recommend AGAINST routine use of cranial radiation for CNS prophylaxis in adolescents and young adults (AYAs) with ALL who are treated on pediatric-inspired (asparaginase-containing) regimens 2. This is a conditional recommendation based on:

  • No demonstrated benefit in overall survival, disease-free survival, or event-free survival when comparing cranial radiation to intensive intrathecal therapy plus systemic chemotherapy with CNS penetration
  • Significant concerns about neurotoxicity and long-term cognitive effects
  • Modern treatment protocols achieving adequate CNS prophylaxis through intensive intrathecal chemotherapy (methotrexate, cytarabine, ± hydrocortisone) combined with systemic agents that penetrate the CNS

When PCI May Still Be Considered

The guidelines acknowledge uncertainty regarding cranial radiation use specifically for AYA patients with T-cell ALL who cannot receive nelarabine 2. Additionally, patients with CNS-3 disease at diagnosis may require cranial radiation depending on their specific treatment protocol 1.

Technical Specifications for Administration

When cranial radiation is administered, proper technique is critical:

  • Field borders must extend 1-2 cm beyond the cranial vault at frontal, vertical, and occipital margins
  • Special attention to adequate coverage of retrobulbar spaces, frontal meninges at the cribriform plate, and temporal meninges in deep cranial fossae
  • Use of lateral opposed fields with isocentric technique
  • Individual blocking with verification at simulation 3, 4

Common Pitfalls

Major deviations in radiation technique occur in approximately 8% of cases and include:

  • Inadequate coverage of the cribriform plate, optic nerves, or temporal lobes
  • Insufficient margins at field borders leading to "geographic miss"
  • These errors are more common at institutions with limited pediatric leukemia experience 3

The key clinical decision is not the dose (which is standardized at 18 Gy), but rather whether cranial radiation should be used at all in the modern era of intensive intrathecal and systemic chemotherapy.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.